NCT05889221 2026-04-30Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple MyelomaPoitiers University HospitalPhase NA Active not recruiting74 enrolled